{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:23:51Z","timestamp":1791599031105,"version":"4.3.4"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Retinal and Eye Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.preteyeres.2020.100921","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T11:53:51Z","timestamp":1606305231000},"page":"100921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"special_numbering":"C","title":["Sustained suppression of VEGF for treatment of retinal\/choroidal vascular diseases"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-8229","authenticated-orcid":false,"given":"Peter A.","family":"Campochiaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-5478","authenticated-orcid":false,"given":"Anam","family":"Akhlaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.preteyeres.2020.100921_bib1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib2","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.preteyeres.2020.100921_bib3","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib4","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1167\/iovs.11-7775","article-title":"Nine-year incidence and risk factors for retinal vein occlusion in a general Japanes population: the Hisayama Study","volume":"52","author":"Arakawa","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib5","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/sj.eye.6702364","article-title":"Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab","volume":"20","author":"Bakri","year":"2006","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2020.100921_bib6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.gt.3302769","article-title":"EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV","volume":"13","author":"Balaggan","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2020.100921_bib7","first-page":"1","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib8","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.neurobiolaging.2014.05.003","article-title":"Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration","volume":"35","author":"Biesemeier","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.preteyeres.2020.100921_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamaophthalmol.2013.4154","article-title":"Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial","volume":"131","author":"Bressler","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.preteyeres.2020.100921_bib10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion:6-month results of the phase III CRUISE study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib12","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2337\/diab.43.6.836","article-title":"Glycation and diabetic complications","volume":"43","author":"Brownlee","year":"1994","journal-title":"Diabetes"},{"key":"10.1016\/j.preteyeres.2020.100921_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2020.100921_bib15","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1172\/JCI129861","article-title":"Low risk to retina from sustained suppression of VEGF","volume":"129","author":"Campochiaro","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.preteyeres.2020.100921_bib16","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.ophtha.2016.04.056","article-title":"Anti-vascular endothelial growth factor agents in the treatment of retinal disease. From bench to bedside","volume":"123","author":"Campochiaro","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","article-title":"Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib18","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1167\/iovs.03-0955","article-title":"Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412","volume":"45","author":"Campochiaro","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ajo.2015.04.025","article-title":"Pro-permeability factors after dexamethasone implant in retinal vein occlusion; the Ozurdex for retinal vein occlusion (ORVO) study","volume":"160","author":"Campochiaro","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2016.04.017","article-title":"Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with Ozurdex study","volume":"168","author":"Campochiaro","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2020.100921_bib23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/hum.2016.117","article-title":"Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study","volume":"28","author":"Campochiaro","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2020.100921_bib25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/hum.2006.17.167","article-title":"Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial","volume":"17","author":"Campochiaro","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2020.100921_bib27","series-title":"38th Annual Scientific Meeting of the American Society of Retina Specialists","article-title":"Primary analysis results of the phase 3 Archway trial of the port delivery system with ranibizumab for patients with neovascular AMD","author":"Campochiaro","year":"2020"},{"key":"10.1016\/j.preteyeres.2020.100921_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN Study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ophtha.2014.03.021","article-title":"Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib30","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Catt Research Group","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2014.09.012","article-title":"Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes","volume":"159","author":"Channa","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib32","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascula age-related macular degeneration. The comparison of age-related macular degeneration treatment trials","volume":"123","author":"Comparison of Age-related Macular Degeneration Treatments Trials (Catt","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib33","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archopht.124.5.726","article-title":"Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study","volume":"124","author":"Cugati","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo\u2013directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib35","first-page":"111","article-title":"Adult-onset macular degeneration in the Cayo Santiago macaques","volume":"8","author":"Dawson","year":"1989","journal-title":"Puert. Rico Health Sci. J."},{"key":"10.1016\/j.preteyeres.2020.100921_bib36","first-page":"977","article-title":"The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complication Trial Research Group","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib37","first-page":"139","article-title":"Ranibizumab for edema of the macula in diabetes trial; 3-year outcomes and the need for prolonged frequent treatment","volume":"131","author":"Do","year":"2013","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib38","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.1073\/pnas.97.22.12222","article-title":"Hyperglycemia-induced mitochondrial superoxide over-production activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation","volume":"97","author":"Du","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.preteyeres.2020.100921_bib39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1110189","article-title":"Complement factor H polymorphism and age-related macular degeneration","volume":"308","author":"Edwards","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.preteyeres.2020.100921_bib41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ejhg.2008.140","article-title":"Variation near complement factor I is associated with risk of advanced AMD","volume":"17","author":"Fagerness","year":"2009","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.preteyeres.2020.100921_bib42","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2020.100921_bib43","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.2337\/diacare.27.2007.S84","article-title":"Retinopathy in diabetes","volume":"27","author":"Fong","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.preteyeres.2020.100921_bib44","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ajpath.2012.12.032","article-title":"VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma","volume":"182","author":"Foxton","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib45","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archopht.1982.01030040110020","article-title":"Histopathologic study of nine branch retinal vein occlusions","volume":"100","author":"Frangieh","year":"1982","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib46","doi-asserted-by":"crossref","first-page":"12409","DOI":"10.1038\/s41598-020-68488-z","article-title":"VEGF is an autocrine\/paracrine neuroprotective factor for injured retinal ganglion neurons","volume":"10","author":"Froger","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2020.100921_bib47","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1534-5807(02)00217-4","article-title":"Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1","volume":"3","author":"Gale","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.preteyeres.2020.100921_bib48","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol T extension study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib49","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib50","first-page":"371","article-title":"Central vein occlusion: a prospective histological study of 29 eyes in 28 cases","volume":"79","author":"Green","year":"1981","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.preteyeres.2020.100921_bib51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7","article-title":"Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization","volume":"184","author":"Hackett","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/jcp.10128","article-title":"Angiopoietin-2 plays an important role in retinal angiogenesis","volume":"192","author":"Hackett","year":"2002","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib54","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1126\/science.1110359","article-title":"Complement factor H variant increases the risk of age-related macular degeneration","volume":"308","author":"Haines","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.preteyeres.2020.100921_bib55","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2337\/diabetes.53.4.1104","article-title":"Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy","volume":"53","author":"Hammes","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.preteyeres.2020.100921_bib56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archopht.1978.03910050179015","article-title":"Experimental retinal vascular occlusion. I. Pathogenesis of central retinal vein occlusion","volume":"96","author":"Hayreh","year":"1978","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib57","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal Aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib58","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"389","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2020.100921_bib60","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1083\/jcb.153.3.543","article-title":"Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis","volume":"153","author":"Hellstrom","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib61","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.preteyeres.2020.100921_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2019.03.029","article-title":"Loss of peak vision in retina vein occlusion patients treated for macular edema","author":"Ifthkhar","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib64","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib65","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ophtha.2014.08.048","article-title":"Long-term effects of therapy with ranibizumab on diabetic retinpathy severity and baseline risk factors for worsening retinopathy","volume":"122","author":"Ip","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib66","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1160\/TH04-11-0768","article-title":"Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors","volume":"93","author":"Janssen","year":"2005","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.preteyeres.2020.100921_bib67","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","article-title":"A central role for inflammation in the pathogenesis of diabetic retinopathy","volume":"18","author":"Joussen","year":"2004","journal-title":"Faseb. J."},{"key":"10.1016\/j.preteyeres.2020.100921_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/hum.2008.046","article-title":"EIAV vector-mediated co-delivery of endostatin and angiostatin driven by the RPE-specific VMD2 promoter inhibits choroidal neovascularization","volume":"20","author":"Kachi","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2020.100921_bib69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exer.2013.03.005","article-title":"Alterations to vascular endothelium in the optic nerve head in patients with vascular comorbidites","volume":"111","author":"Kang","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.preteyeres.2020.100921_bib70","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/01.RES.0000102937.50486.1B","article-title":"Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1","volume":"93","author":"Kelly","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.preteyeres.2020.100921_bib71","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1167\/iovs.15-18904","article-title":"Quantifying microvascular density and morphology in diabetic retinopathy using spectral-domain optical choherence tomography angiography","volume":"57","author":"Kim","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09286580701396720","article-title":"Overview of epidemiologic studies of diabetic retinopathy","volume":"14","author":"Klein","year":"2007","journal-title":"Ophthalmic Epidemiol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib73","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.preteyeres.2020.100921_bib74","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.126.4.513","article-title":"The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study","volume":"126","author":"Klein","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib75","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.preteyeres.2020.100921_bib76","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib77","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates","volume":"22","author":"Kotterman","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2020.100921_bib78","first-page":"1","article-title":"Oxidative stress and diabetic retinopathy","author":"Kowluru","year":"2007","journal-title":"Exp. Diabetes Res."},{"key":"10.1016\/j.preteyeres.2020.100921_bib79","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","article-title":"Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment","volume":"120","author":"Kryzstolik","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib80","doi-asserted-by":"crossref","DOI":"10.1172\/JCI65157","article-title":"Targeted deletion of Vegfa in adult mice induces vision loss","volume":"122","author":"Kurihara","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.preteyeres.2020.100921_bib81","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archopht.1963.00960040498013","article-title":"Retinal vascular patterns VI: mural cells of the retinal capillaries","volume":"69","author":"Kuwabara","year":"1963","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib82","first-page":"3158","article-title":"VEGF is an important stimulator in a model of choroidal neovascularization","volume":"41","author":"Kwak","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib83","first-page":"2401","article-title":"Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin","volume":"42","author":"Lai","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib84","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.preteyeres.2020.100921_bib85","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration. A randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib86","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.277.5323.242","article-title":"Pericyte loss and microaneurysm formation in PDGF-B-deficient mice","volume":"277","author":"Lindahl","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.preteyeres.2020.100921_bib87","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ymthe.2017.12.002","article-title":"AAV8-anti-VEGFfab ocular gene transfer for neovascular age-related macular degeneration","volume":"26","author":"Liu","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2020.100921_bib88","doi-asserted-by":"crossref","first-page":"95530","DOI":"10.1172\/jci.insight.95530","article-title":"Reversible retinal vessel closure from VEGF-inudce leukocyte plugging","volume":"2","author":"Liu","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.preteyeres.2020.100921_bib89","doi-asserted-by":"crossref","first-page":"120231","DOI":"10.1172\/jci.insight.120231","article-title":"VEGF\/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models","volume":"3","author":"Long","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.preteyeres.2020.100921_bib90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1096\/fba.2019-00074","article-title":"Hepatocyte growth factor is upregulated in ishemic retina and contributes to retinal vascular leakage and neovascularization","volume":"2","author":"Lorenc","year":"2020","journal-title":"FASEB Bioadv"},{"key":"10.1016\/j.preteyeres.2020.100921_bib91","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/mt.2010.258","article-title":"Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration","volume":"19","author":"Maclachlan","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2020.100921_bib92","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1167\/iovs.09-3639","article-title":"Relationship between RPE and choriocapillaris in age-related macular degeneration","volume":"50","author":"McLeod","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2020.100921_bib94","first-page":"327","article-title":"In vivo activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2013","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.preteyeres.2020.100921_bib95","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib96","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jcp.22129","article-title":"Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells","volume":"224","author":"Miki","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib97","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ophtha.2015.10.030","article-title":"Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion","volume":"123","author":"Mir","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib98","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.oret.2018.02.011","article-title":"Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies","volume":"2","author":"Mitchell","year":"2019","journal-title":"Ophthalmology Retina"},{"key":"10.1016\/j.preteyeres.2020.100921_bib99","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0002-9440(10)61697-5","article-title":"Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin","volume":"159","author":"Mori","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jcp.1114","article-title":"Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization","volume":"188","author":"Mori","year":"2001","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib101","first-page":"1994","article-title":"AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization","volume":"43","author":"Mori","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib102","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.ophtha.2006.05.070","article-title":"Systemic Bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twenty-four-week results of an uncontrolled open-label clinical study","volume":"113","author":"Moshfeghi","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib103","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.preteyeres.2020.100921_bib104","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1167\/iovs.10-6476","article-title":"Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration","volume":"52","author":"Mullins","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib105","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.ajpath.2014.07.017","article-title":"The membrane attack complex in aging human choriocapillaris. Relationship to macular degeneration and choroidal thinning","volume":"184","author":"Mullins","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib106","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema. Results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib107","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ajo.2007.09.025","article-title":"Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration","volume":"145","author":"Nguyen","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib108","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib109","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1167\/iovs.03-0557","article-title":"Supplemental inspired oxygen improves diabetic macular edema; a pilot study","volume":"45","author":"Nguyen","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib110","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","article-title":"Vascular endothelial growth factor is a critical stimulus for diabetic macular edema","volume":"142","author":"Nguyen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib111","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/35008121","article-title":"Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage","volume":"404","author":"Nishikawa","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.preteyeres.2020.100921_bib112","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2014.09.025","article-title":"Neurons limit angiogenesis by titrating VEGF in retina","volume":"159","author":"Okabe","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.preteyeres.2020.100921_bib113","first-page":"281","article-title":"Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization","volume":"151","author":"Okamoto","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib114","first-page":"182","article-title":"Hypoxia inducible factor-1a is increased in ischemic retina: temporal and spatial correlation with VEGF expression","volume":"40","author":"Ozaki","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib115","doi-asserted-by":"crossref","first-page":"15296","DOI":"10.1038\/ncomms15296","article-title":"Plastic roles of pericytes in the blood-retinal barrier","volume":"8","author":"Park","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2020.100921_bib116","first-page":"236","article-title":"Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration","volume":"4","author":"Pfau","year":"2020","journal-title":"Opthalmol. Retina"},{"key":"10.1016\/j.preteyeres.2020.100921_bib117","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomized clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2020.100921_bib118","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ajo.2019.03.006","article-title":"Three-year follow-up of Phase 1 and 2a rAAV.sFLT1 subretinal gene therapy trials for exudative age-related macular degeneration","volume":"204","author":"Rakoczy","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib119","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovasuclar age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib121","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib122","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib123","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intavitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg. Laser. Imag."},{"key":"10.1016\/j.preteyeres.2020.100921_bib124","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ophtha.2011.09.027","article-title":"Age and gender variations in age-related macular degneration prevalence in populations of European ancestry: a meta-analysis","volume":"119","author":"Rudnicka","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib125","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1001\/archopht.1982.01030040784015","article-title":"Subretinal neovascularization: natural history of an experimental model","volume":"100","author":"Ryan","year":"1982","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib126","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jcp.10246","article-title":"VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier","volume":"195","author":"Saishin","year":"2003","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib127","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/bjo.60.5.324","article-title":"Ageing and degeneration in the macular region: a clinicopathologic study","volume":"60","author":"Sarks","year":"1976","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib128","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1167\/iovs.07-1072","article-title":"Complement-associated deposits in the human retina","volume":"49","author":"Seth","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib129","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1172\/JCI74527","article-title":"Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature","volume":"124","author":"Shen","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.preteyeres.2020.100921_bib130","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.ophtha.2015.07.034","article-title":"Diabetic retinopathy severity and peripheral lesions are associated with nonperfusion on ultrawide field angiography","volume":"122","author":"Silva","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-5793(04)00297-2","article-title":"The effect of angiostatin on vascular leakage and VEGF expression in rat retina","volume":"564","author":"Sima","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.preteyeres.2020.100921_bib132","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/bjo.2010.179945","article-title":"The growing importance of pharmacoeconomics: the case of age-related macular degeneration","volume":"94","author":"Smith","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib133","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.ajpath.2019.04.005","article-title":"Choriocapillaris degeneration in geographic atrophy","volume":"189","author":"Sohn","year":"2019","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib134","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ajo.2013.05.039","article-title":"Long term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion","volume":"156","author":"Sophie","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib135","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1096\/fj.02-0824fje","article-title":"Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment","volume":"17","author":"Takahashi","year":"2003","journal-title":"Faseb. J."},{"key":"10.1016\/j.preteyeres.2020.100921_bib136","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ophtha.2019.03.044","article-title":"Swept-source OCT for evaluating the lamina cribrosa","volume":"126","author":"Takusagawa","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib137","doi-asserted-by":"crossref","first-page":"6612","DOI":"10.1038\/s41598-019-42649-1","article-title":"Changes in the anterior lamina cribrosa morphology with glaucoma severity","volume":"9","author":"Tan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2020.100921_bib138","first-page":"320","article-title":"Morphometric assessment of the central retinal artery and vein in the optic nerve head","volume":"28","author":"Taylor","year":"1993","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib139","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"The Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib140","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. One year findings from the IVAN randomized trial","volume":"119","author":"The Ivan Study Investigators","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib141","first-page":"180","article-title":"Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors","volume":"39","author":"Tobe","year":"1998","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib142","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0002-9440(10)65753-7","article-title":"Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model","volume":"153","author":"Tobe","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib143","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41467-020-14340-x","article-title":"Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles","volume":"11","author":"Tsujinaka","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2020.100921_bib144","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.21445","article-title":"Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels","volume":"217","author":"Ueno","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2020.100921_bib146","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/jcp.20525","article-title":"Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development","volume":"206","author":"Vinores","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib147","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1073\/pnas.1211284110","article-title":"Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death","volume":"110","author":"Welsbie","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.preteyeres.2020.100921_bib148","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bjo.2006.102798","article-title":"A \"throttle\" mechanism in the central retinal vein in the region of the lamina cribrosa","volume":"91","author":"Williamson","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2020.100921_bib149","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Writing Committee for the Diabetic Retinopathy Clinical Research Network","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib150","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2020.100921_bib151","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1172\/JCI80297","article-title":"Neruovascular crosstalk between interneurons an capillaries is required for vision","volume":"125","author":"Yoshihiko","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.preteyeres.2020.100921_bib152","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ophtha.2014.05.012","article-title":"Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema","volume":"121","author":"Zhang","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2020.100921_bib153","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0161-6420(93)31633-7","article-title":"Arteriovenous crossing patterns in branch retinal vein occlusion: the Eye Disease Case-Control Study Group","volume":"100","author":"Zhao","year":"1993","journal-title":"Ophthalmology"}],"container-title":["Progress in Retinal and Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946220300938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946220300938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:36:48Z","timestamp":1761172608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1350946220300938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":153,"alternative-id":["S1350946220300938"],"URL":"https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100921","relation":{},"ISSN":["1350-9462"],"issn-type":[{"value":"1350-9462","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained suppression of VEGF for treatment of retinal\/choroidal vascular diseases","name":"articletitle","label":"Article Title"},{"value":"Progress in Retinal and Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100921"}}